Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)

NCT00100737 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin Lymphoma

Interventions

DRUG: interleukin-2
DRUG: rituximab

Sponsor

Chiron Corporation